QPS Neuropharmacology is highly experienced in generating, characterizing, and maintaining transgenic disease models and using them for drug testing projects for more than 20 years.
The mouse and rat models available for drug development in Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Huntington’s Disease (HD), Niemann-Pick Disease (NPC1), Gaucher Disease, Amyotrophic Lateral Sclerosis (ALS) , Autism Spectrum Disorder (ASD), Schizophrenia, Frontotemporal Lobar Degeneration (FTLD), and other neurodegenerative and rare diseases allow the quantitative evaluation of compound interactions with amyloid, tau, NPC1, SOD1, TDP-43, HTT, inflammation related markers, mitochondrial deficiency and other pathologies.
We are happy to receive your inquiry to elaborate the most efficient way, including behavioral, immunohistochemical, biochemical and molecular biological techniques, to support your drug development approach.
The biobank can provide samples (brain tissue, CSF, organs, etc.) of our animal models for analyses in your laboratory.